Market Closed -
Nasdaq
16:00:00 2024-05-10 EDT
5-day change
1st Jan Change
15.72
USD
-4.78%
-3.91%
+23.29%
Presentation Operator MessageOperator (Operator)Good afternoon, and welcome to the Curis' Seco...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-07
CI
Transcript : Curis, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07
Earnings Flash (CRIS) CURIS Reports Q1 Revenue $2.1M, vs. Street Est of $2M
05-07
MT
HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating
02-09
MT
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-08
CI
Transcript : Curis, Inc., Q4 2023 Earnings Call, Feb 08, 2024
02-08
Earnings Flash (CRIS) CURIS Reports Q4 Revenue $2.7M, vs. Street Est of $3.1M
02-08
MT
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-08
CI
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study
12-12
CI
Curis, Inc. Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
12-05
CI
Truist Starts Curis With Buy Rating
11-17
MT
Transcript : Curis, Inc., Q3 2023 Earnings Call, Nov 02, 2023
11-02
Earnings Flash (CRIS) CURIS Posts Q3 Revenue $2.8M, vs. Street Est of $2.6M
11-02
MT
Curis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-02
CI
India's contaminated cough syrup cases
23-09-13
RE
Transcript : Curis, Inc., Q2 2023 Earnings Call, Aug 03, 2023
23-08-03
Earnings Flash (CRIS) CURIS Reports Q2 Revenue $2.2M, vs. Street Est of $2.5M
23-08-03
MT
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-03
CI
Taseko Mines Provided Financing Update For Florence Copper
23-07-13
MT
HC Wainwright Cuts Price Target on Curis to $6 From $9, Maintains Buy Rating
23-07-07
MT
Sector Update: Health Care Stocks Softer Late Thursday
23-07-06
MT
Sector Update: Health Care Stocks Down Thursday Afternoon
23-07-06
MT
Curis Says FDA Removes Partial Clinical Hold on Emavusertib Phase 1/2 Study
23-07-06
MT
U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID
23-07-06
CI
Curis, Inc.(NasdaqCM:CRIS) dropped from Russell Microcap Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
More about the company
Last Close Price
15.72
USD
Average target price
79.8
USD
Spread / Average Target
+407.63%
Consensus
1st Jan change
Capi.
+23.29% 92.66M +17.96% 44.96B +1.17% 42.65B +48.77% 41.85B -4.27% 29.04B +11.42% 26.08B -21.39% 19.03B +4.86% 12.75B +27.29% 12.06B -3.50% 11.75B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1